Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. - Archive ouverte HAL Access content directly
Journal Articles Antiviral Therapy Year : 2008

Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.

(1, 2) , (3) , (1) , (1) , (4) , (5) , (6, 7) , (8) , (9) , (6, 7) , (1, 2)
1
2
3
4
5
6
7
8
9

Abstract

BACKGROUND: Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients. METHODS: This open-label study compared the HBV dynamics in 85 HIV-HBV-coinfected patients initiating an antiretroviral regimen, either including TDF or associated with ADV. The first 6-month change in viral load was analysed using mixed linear models. The adjusted hazards ratio, comparing the rates of undetectable HBV DNA between treatments, was calculated using a Cox proportional hazard model. RESULTS: The HBV DNA decay, adjusted for baseline HBV viral load was more pronounced in patients treated with TDF than with ADV at 12 months (66% versus 53%, P=0.0001). Patients in the TDF group presented a steeper slope of decline at 1.1 (95% confidence interval [CI] 0.9-1.3), compared with 0.8 (95% CI 0.6-1.0) in the ADV group (P=0.036). The mean time to HBV DNA undetectability was 19.3 months (95% CI 16.7-22.0) with TDF and 25.9 months (95% CI 21.1-30.7) with ADV. When adjusted for hepatitis B virus e antigen, HBV DNA and alanine aminotransferase levels at baseline, the influence of treatment on time to HBV DNA undetectability remained in favour of TDF versus ADV (hazard ratio=2.79, 95% CI 1.05-7.40, P=0.039) CONCLUSIONS: TDF influenced more strongly the early-phase HBV DNA kinetics than ADV. This is associated with a sustained antiviral activity in the TDF group, in which patients reached the threshold of HBV undetectability at a faster rate and in a larger proportion than those taking ADV.
Fichier principal
Vignette du fichier
ADV_TDF_figure_2_REVISED.pdf (12.61 Ko) Télécharger le fichier
Vignette du fichier
ADV_TDF_figure_1_REVISED.pdf (48.32 Ko) Télécharger le fichier
Vignette du fichier
ADV_TDF_figure_3_REVISED.pdf (6.53 Ko) Télécharger le fichier
Vignette du fichier
ADV_TDF_HAL.pdf (103.45 Ko) Télécharger le fichier
Vignette du fichier
ADV_TDF_tables_REVISED.pdf (17.41 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)

Dates and versions

inserm-00325812 , version 1 (30-09-2008)

Identifiers

  • HAL Id : inserm-00325812 , version 1
  • PUBMED : 18771054

Cite

Karine Lacombe, Joël Gozlan, Anders Boyd, Pierre-Yves Boelle, Philippe Bonnard, et al.. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.. Antiviral Therapy, 2008, 13 (5), pp.705-13. ⟨inserm-00325812⟩
149 View
752 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More